Crown Laboratories, Inc. on Monday announced an amended and restated agreement to acquire all outstanding shares of Revance Therapeutics, Inc. (RVNC) for $3.10 per share in cash.
The new deal comes in response to several developments with Revance, such as its settlement with Teoxane for alleged breach of distribution agreement, its prospects as a standalone company, and its recent commercial performance relative to prior 2024 financial guidance.
Following the transaction, which is expected to be completed in the first quarter of 2025, Revance's stock will be delisted on the Nasdaq.
Currently, Revance's stock is falling 20.39 percent, to $3.04 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.